These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 8763844)
1. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844 [TBL] [Abstract][Full Text] [Related]
2. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism. Siim BG; Hicks KO; Pullen SM; van Zijl PL; Denny WA; Wilson WR Biochem Pharmacol; 2000 Oct; 60(7):969-78. PubMed ID: 10974206 [TBL] [Abstract][Full Text] [Related]
3. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity. Lee HH; Wilson WR; Denny WA Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270 [TBL] [Abstract][Full Text] [Related]
4. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448 [TBL] [Abstract][Full Text] [Related]
5. Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. Wilson WR; Van Zijl P; Denny WA Int J Radiat Oncol Biol Phys; 1992; 22(4):693-6. PubMed ID: 1544839 [TBL] [Abstract][Full Text] [Related]
6. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Hejmadi MV; McKeown SR; Friery OP; McIntyre IA; Patterson LH; Hirst DG Br J Cancer; 1996 Feb; 73(4):499-505. PubMed ID: 8595165 [TBL] [Abstract][Full Text] [Related]
7. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Patterson LH Cancer Metastasis Rev; 1993 Jun; 12(2):119-34. PubMed ID: 8375016 [TBL] [Abstract][Full Text] [Related]
8. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Patterson LH; Craven MR; Fisher GR; Teesdale-Spittle P Oncol Res; 1994; 6(10-11):533-8. PubMed ID: 7620222 [TBL] [Abstract][Full Text] [Related]
9. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. Hicks KO; Pruijn FB; Baguley BC; Wilson WR J Pharmacol Exp Ther; 2001 Jun; 297(3):1088-98. PubMed ID: 11356933 [TBL] [Abstract][Full Text] [Related]
10. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. McKeown SR; Hejmadi MV; McIntyre IA; McAleer JJ; Patterson LH Br J Cancer; 1995 Jul; 72(1):76-81. PubMed ID: 7599069 [TBL] [Abstract][Full Text] [Related]
11. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Patterson LH Drug Metab Rev; 2002 Aug; 34(3):581-92. PubMed ID: 12214668 [TBL] [Abstract][Full Text] [Related]
12. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Patterson LH; McKeown SR Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551 [TBL] [Abstract][Full Text] [Related]
13. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine. Wilson WR; Siim BG; Denny WA; van Zijl PL; Taylor ML; Chambers DM; Roberts PB Radiat Res; 1992 Sep; 131(3):257-65. PubMed ID: 1438685 [TBL] [Abstract][Full Text] [Related]
14. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036 [TBL] [Abstract][Full Text] [Related]
15. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024 [TBL] [Abstract][Full Text] [Related]
16. Effects of AQ4N and its reduction product on radiation-mediated DNA strand breakage. Ali MM; Symons MC; Taiwo FA; Patterson LH Chem Biol Interact; 1999 Nov; 123(1):1-10. PubMed ID: 10597898 [TBL] [Abstract][Full Text] [Related]
17. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Gallagher R; Hughes CM; Murray MM; Friery OP; Patterson LH; Hirst DG; McKeown SR Br J Cancer; 2001 Aug; 85(4):625-9. PubMed ID: 11506506 [TBL] [Abstract][Full Text] [Related]
18. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry. Atkinson SJ; Loadman PM; Sutton C; Patterson LH; Clench MR Rapid Commun Mass Spectrom; 2007; 21(7):1271-6. PubMed ID: 17340571 [TBL] [Abstract][Full Text] [Related]
19. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Patterson LH; McKeown SR; Ruparelia K; Double JA; Bibby MC; Cole S; Stratford IJ Br J Cancer; 2000 Jun; 82(12):1984-90. PubMed ID: 10864207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]